This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Biogen, Inc.

Drug Names(s): anti-CD40L

Description: IDEC-131 is a humanized monoclonal antibody that targets the CD40 ligand on T Cells. T cells interact with and regulate antibody producing B cells through mechanisms that include this cell-surface marker. IDEC-131 functions by binding to CD40 ligand, which reduces the production of antibodies by B cells.

Deal Structure: Eisai will market IDEC-131 in Europe and Asia.

Partners: Eisai Co., Ltd.

IDEC-131 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug